This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms
Study Type
OBSERVATIONAL
Enrollment
6,876
As per product label
Veradigm
Chicago, Illinois, United States
Number of all-cause and schizophrenia-related healthcare encounters per participant
Number of inpatient admissions, emergency room visits, urgent care visits, and outpatient visits identified from claims and EHR data. Schizophrenia-related encounters are defined as those with a primary diagnosis of schizophrenia using ICD-10-CM codes.
Time frame: Baseline and up to 6 months
Number of participants adherent to KarXT (proportion of days covered ≥80%)
Adherence measured using proportion of days covered (PDC), defined as total days of KarXT supply divided by total number of days in the follow-up period. Participants with PDC ≥80% are classified as adherent. Reported as number and percentage of participants meeting adherence criteria.
Time frame: Baseline and up to 6 months
Time to discontinuation of KarXT
Time from index date (first KarXT prescription) to discontinuation, defined as a gap of ≥45 consecutive days without KarXT supply.
Time frame: Baseline and up to 6 months
KarXT initial dose (index dose)
Distribution of index dose (50 mg/20 mg, 100 mg/20 mg, 125 mg/30 mg, or starter pack)
Time frame: Baseline
Number of of participants with dose increases or decreases
Time frame: Baseline and up to 6 months
Number of participants using concomitant antipsychotic and anticholinergic medications
Time frame: Baseline and up to 6 months
Number of participants with comorbidities
Time frame: Baseline and up to 6 months
Number of participants with gastrointestinal adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline and up to 6 months
Number of participants with documented schizophrenia symptoms
Presence of positive and negative schizophrenia symptoms identified using natural language processing (NLP) of unstructured clinical notes, including hallucinations, delusions, disorganized thought, amotivation, avolition, anhedonia, asociality, alogia, and blunted affect.
Time frame: Baseline and up to 6 months